References
- Hefazi M, Damlaj M, Alkhateeb HB, et al. The impact of ferbrile neutropenia after allogeneic hematopoietic cell transplantation on graft-versus-host disease and relapse in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23:S18–S391S.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Disease Society of America. Clin Infect Dis. 2011;52(4):e56–93.
- Libuit J, Whitman A, Wolfe R, et al. Empiric vancomycin use in febrile neutropenic oncology patients. Open Forum Infect Dis. 2014;1(1):1–3.
- Cometta A, Kern WV, De Bock R, International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382–389.
- Jaffe D, Jakubowski A, Sepkowitz K, et al. Prevention of peritransplantation viridans Streptococcal bacteremia with early vancomycin administration: a single-center observational cohort study. Clin Infect Dis. 2004;39(11):1625–1632.
- Attal M, Schlaifer D, Rubie H, et al. Prevention of Gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. J Clin Oncol. 1991;9(5):865–870.
- Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66:82–98.
- Yasu T, Konuma T, Oiwa-Monna M, et al. Lower vancomycin trough levels in adults undergoing unrelated cord blood transplantation. Leuk Lymphoma. 2021;62(2):348–357.
- Tarai B, Das P, Kumar D. Recurrent challenges for clinicians: emergence of methicillin-resistant Staphylococcus aureus, vancomycin resistance, and current treatment options. J Lab Physicians. 2013;5(02):071–078.
- Vydra J, Shanley RM, George I, et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55(6):764–777.
- Zaas AK, Song X, Tucker P, et al. Risk factors for development of vancomycin-resistant Enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant Enterococci. Clin Infect Dis. 2002;35(10):1139–1146.
- Wan M, Walker SA, Martin E, et al. The impact of vancomycin trough concentrations on outcomes in non-deep seated infections: a retrospective cohort study. BMC Pharmacol Toxicol. 2018;19(1):47.
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835–863.